Table 3.
Secondary outcome measures (binary)
| Binary outcomes | Total No, No (%) of participants | Relative risk (95% CI) | P | |
|---|---|---|---|---|
| CSII (n=144) | MDI (n=149) | |||
| HbA1c <58 mmol/mol*† | 143, 66 (46.2) | 142, 78 (54.9) | 0.84 (0.67 to 1.06) | 0.16 |
| HbA1c <48 mmol/mol*† | 143, 22 (15.4) | 142, 29 (20.4) | 0.75 (0.46 to 1.25) | 0.28 |
| Incidence of severe hypoglycaemia* | 144, 6 (4.2) | 149, 2 (1.3) | 3.1 (0.6 to 15.1) | 0.17 |
| Incidence of diabetic ketoacidosis* | 144, 2 (1.4) | 149, 0 | 5.2 (0.3 to 106.8) | 0.24 |
| Partial remission (IDAAC <9)* | 86, 21 (24.4) | 64, 21 (32.8) | 0.74 (0.45 to 1.24) | 0.28 |
CSII=continuous subcutaneous insulin infusion; MDI=multiple daily injections; IDAAC=insulin dose adjusted glycated haemoglobin (HbA1c).
*
Intention-to-treat analysis.
†
58 mmol/mol was the national target up to August 2015; 48 mmol/mol was the target set in August 2015.